Ted Torphy.jpg


Ted Torphy, PhD

Ted Torphy, PhD, is Chief Executive Officer and Chief Scientific Officer of BioMotiv. Dr. Torphy, brings over 30 years of experience in the pharmaceutical industry with a successful record in both small-molecule and large-molecule drug discovery and preclinical development. In addition to his role with BioMotiv, he is a member of the Innovation Support Center of the Harrington Discovery Institute and Board Chairman, Cystic Fibrosis Therapeutics, Inc. Ted also serves on the Board of Directors of several additional for-profit and non-profit organizations.

Prior to joining BioMotiv, Ted spent 12 years with Johnson & Johnson Pharmaceuticals. His roles included Global Head of External Innovation & Business Models for Discovery Sciences, Vice President and Head of External Research and Early Development, and Corporate Vice President and Head of Johnson & Johnson’s Corporate Office of Science & Technology. In addition, he spent four years at Centocor, the biopharmaceutical arm of Johnson & Johnson, as Senior Vice President and Head of Discovery and Preclinical Development. During this period SIMPONI®, STELARA® and SYLVANT® entered the Discovery portfolio. Prior to joining Centocor, he spent 17 years with SmithKline Beecham, most recently as Vice President and Head of Biological Research for the Cardiovascular, Pulmonary, Renal, Metabolic Diseases, and Inflammation therapeutic areas.

Since 2006, Ted has chaired the Board of Directors of the Cystic Fibrosis Foundation Therapeutics, Inc. During his Board tenure, the Foundation initiated its pioneering venture philanthropy drug discovery program. This program led to the introduction of multiple new therapies, including Vertex Pharmaceuticals’ development and launch of KALYDECO® and ORKAMBI®, the first treatments that correct the fundamental defect causing cystic fibrosis.

Ted is the author of more than 120 journal articles, review articles, book chapters, and patents, and served on the editorial boards of numerous scientific journals. He holds a B.S. degree in Pharmacy from the University of Wisconsin and a Ph.D. in Pharmacology and Toxicology from West Virginia University. He completed his postdoctoral training at the University of California, San Diego.